Marcus Schabacker - 23 Dec 2025 Form 4 Insider Report for Enveric Biosciences, Inc. (ENVB)

Reporting relationship: Director
Issuer ticker: ENVB
Reported as of: 23 Dec 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 30 Dec 2025, 16:39:53 UTC
Prior SEC filing: 11 Oct 2024
Next SEC filing: 03 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Marcus Schabacker

Key filing fact

Marcus Schabacker filed Form 4 for Enveric Biosciences, Inc. (ENVB) on 30 Dec 2025.

Key facts

This page summarizes Marcus Schabacker's Form 4 filing for Enveric Biosciences, Inc. (ENVB).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 30 Dec 2025, 16:39.

Change

Previous filing in this sequence was filed on 11 Oct 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001645282 Primary reporting owner

Schabacker Marcus

Relationship: Director
Address: 245 FIRST STREET, RIVERVIEW II, 18TH FLOOR, CAMBRIDGE
Signature: /s/ Marcus Schabacker
Signature date: 30 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ENVB transaction

Common Stock

Award

Transaction value: $0
Shares: +7,633
Change %: +2859%
Price: $0.000000
Shares after: 7,900
Date: 23 Dec 2025
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the "Plan"). Such shares shall vest in accordance with the terms and conditions of the Plan and the reporting person's restricted stock award agreement.

Footnote F2

On January 29, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 15 shares of issued and outstanding common stock were reclassified as one share of common stock (the "January Reverse Stock Split"). On October 28, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 12 shares of issued and outstanding common stock were reclassifed as one share of common stock (the"October Reverse Stock Split" together with the January Reverse Stock Split, the "Reverse Stock Splits"). The number of securities reported in this Form 4 has been adjusted to reflect the Reverse Stock Splits.